Age-specific effects of vaccine egg adaptation and immune priming on A(H3N2) antibody responses following influenza vaccination.


Journal

The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877

Informations de publication

Date de publication:
15 04 2021
Historique:
received: 17 11 2020
accepted: 03 03 2021
pubmed: 11 3 2021
medline: 29 9 2021
entrez: 10 3 2021
Statut: ppublish

Résumé

A(H3N2) influenza vaccine effectiveness (VE) was low during the 2016-19 seasons and varied by age. We analyzed neutralizing antibody responses to egg- and cell-propagated A(H3N2) vaccine and circulating viruses following vaccination in 375 individuals (aged 7 months to 82 years) across all vaccine-eligible age groups in 3 influenza seasons. Antibody responses to cell- versus egg-propagated vaccine viruses were significantly reduced due to the egg-adapted changes T160K, D225G, and L194P in the vaccine hemagglutinins. Vaccine egg adaptation had a differential impact on antibody responses across the different age groups. Immunologically naive children immunized with egg-adapted vaccines mostly mounted antibodies targeting egg-adapted epitopes, whereas those previously primed with infection produced broader responses even when vaccinated with egg-based vaccines. In the elderly, repeated boosts of vaccine egg-adapted epitopes significantly reduced antibody responses to the WT cell-grown viruses. Analysis with reverse genetic viruses suggested that the response to each egg-adapted substitution varied by age. No differences in antibody responses were observed between male and female vaccinees. Here, the combination of age-specific responses to vaccine egg-adapted substitutions, diverse host immune priming histories, and virus antigenic drift affected antibody responses following vaccination and may have led to the low and variable VE against A(H3N2) viruses across different age groups.

Identifiants

pubmed: 33690218
pii: 146138
doi: 10.1172/JCI146138
pmc: PMC8262463
doi:
pii:

Substances chimiques

Antibodies, Viral 0
Influenza Vaccines 0

Types de publication

Journal Article Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Références

Immunol Rev. 2020 Jul;296(1):191-204
pubmed: 32666572
J Infect Dis. 2019 Jul 31;220(5):820-829
pubmed: 31053844
Clin Infect Dis. 2020 Nov 5;71(8):e368-e376
pubmed: 31905401
MMWR Morb Mortal Wkly Rep. 2018 Feb 16;67(6):180-185
pubmed: 29447141
J Infect Dis. 1989 Aug;160(2):191-8
pubmed: 2760480
Science. 2014 Nov 21;346(6212):996-1000
pubmed: 25414313
J Infect Dis. 2019 May 24;219(12):1904-1912
pubmed: 30721982
J Infect Dis. 2016 Oct 1;214(7):1010-9
pubmed: 27190176
Proc Natl Acad Sci U S A. 2014 Nov 4;111(44):15798-803
pubmed: 25331901
Clin Infect Dis. 2019 Nov 13;69(11):1845-1853
pubmed: 30715278
Vaccine. 2010 May 28;28(24):4079-85
pubmed: 20399830
J Infect Dis. 2018 Jun 20;218(2):189-196
pubmed: 29361005
J Infect Dis. 2017 Sep 15;216(suppl_4):S539-S547
pubmed: 28934461
MMWR Morb Mortal Wkly Rep. 2019 Jun 21;68(24):544-551
pubmed: 31220057
J Virol. 2010 Jan;84(1):44-51
pubmed: 19864389
J Virol. 2015 Apr;89(7):3763-75
pubmed: 25609810
Sci Transl Med. 2013 Aug 14;5(198):198ra107
pubmed: 23946196
Euro Surveill. 2019 Nov;24(46):
pubmed: 31771709
J Clin Invest. 2015 Jul 1;125(7):2631-45
pubmed: 26011643
Science. 2010 Apr 16;328(5976):357-60
pubmed: 20339031
Nat Med. 2016 Dec;22(12):1465-1469
pubmed: 27820604
Science. 2013 Nov 22;342(6161):976-9
pubmed: 24264991
MMWR Morb Mortal Wkly Rep. 2017 Feb 17;66(6):167-171
pubmed: 28207689
Euro Surveill. 2019 Nov;24(48):
pubmed: 31796152
Clin Infect Dis. 2019 May 17;68(11):1798-1806
pubmed: 30204854
J Infect Dis. 2018 Oct 5;218(10):1571-1581
pubmed: 29931203
Proc Natl Acad Sci U S A. 2017 Nov 21;114(47):12578-12583
pubmed: 29109276
PLoS Pathog. 2017 Oct 23;13(10):e1006682
pubmed: 29059230
Nat Commun. 2020 Sep 11;11(1):4566
pubmed: 32917903
Science. 2016 Nov 11;354(6313):722-726
pubmed: 27846599
J Infect Dis. 2020 Jan 1;221(1):8-15
pubmed: 31665373
J Gen Virol. 1993 Jul;74 ( Pt 7):1311-6
pubmed: 8336120
J Exp Med. 2013 Jul 29;210(8):1493-500
pubmed: 23857983
J Vis Exp. 2017 Nov 22;(129):
pubmed: 29286446
J Infect Dis. 2020 Sep 14;222(8):1371-1382
pubmed: 32496543
Virology. 1993 Sep;196(1):130-7
pubmed: 8356790

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH